Dianthus Therapeutics (DNTH) closed at $84.55 on November 20, 2026, down 0.3% from the previous close, on volume of 759,411 shares (30-day average 892,712).
Data as of November 20, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Strangle or Risk Reversal | 20-Nov-2680 P : 95 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Dianthus Therapeutics (DNTH)
TipRanks (Mon, 16-Nov 10:00 AM ET)
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 2-Nov 5:00 PM ET)
Dianthus Therapeutics to Participate in Five Investor Conferences During November
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
Globe Newswire (Tue, 13-Oct 8:45 AM ET)
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Market Chameleon (Wed, 11-Mar 4:16 AM ET)
Dianthus Therapeutics Sparks Attention with Phase 3 CIDP Trial Update—Market Awaits Conference Call
Market Chameleon (Mon, 9-Mar 6:32 AM ET)
DNTH Secures Early Phase 3 Milestone in CIDP as Cash Runway Extends Into 2028
Market Chameleon (Mon, 9-Mar 3:57 AM ET)
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.
As of November 20, 2026, DNTH stock price declined to $84.55 with 759,411 million shares trading.
DNTH has a beta of -0.13, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.00 to the broad based SPY ETF.
DNTH has a market cap of $4.76 billion. This is considered a Mid Cap stock.
Last quarter Dianthus Therapeutics reported $1 million in Revenue and -$.81 earnings per share. This beat revenue expectation by $759,072 and exceeded earnings estimates by $.15.
In the last 3 years, DNTH traded as high as $117.88 and as low as $6.58.
The top ETF exchange traded funds that DNTH belongs to (by Net Assets): XBI, VTI, IWM, VXF, VB.
DNTH has outperformed the market in the last year with a price return of +107.3% while the SPY ETF gained +5.2%. However, in the short term, DNTH had mixed performance relative to the market. It has underperformed in the last 3 months, returning -25.6% vs -10.1% return in SPY. But in the last 2 weeks, DNTH shares have fared better than the market returning +1.9% compared to SPY -5.9%.
DNTH support price is $81.92 and resistance is $87.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.